United States: It's Time To Change How Antibodies Are Claimed In Patent Strategy - Oblon, McClelland, Maier & Neustadt, L.L.P

United States: It's Time To Change How Antibodies Are Claimed In Patent Strategy - Oblon, McClelland, Maier & Neustadt, L.L.P

Mondaq

Published

The US Supreme Court announced its ruling May 18 in favor of Sanofi in its dispute with Amgen over the enablement requirement as it pertained to antibody claims.

Full Article